Is JAMA a Good Journal? What Physicians and Researchers Need to Know

JAMA desk-rejects most research manuscripts within 48 hours. That's not a typo. The editors read the title, Key Points, structured abstract, and sometimes the first figure, and they know whether the paper belongs here.

What survives the 2-day screen:

• Research that changes what a general internist does for patients, not "might eventually influence" but "should change practice now"

• Multi-center studies with adequate power (single-center studies are almost never accepted unless the condition is extraordinarily rare)

• Clinical significance, not just statistical significance, effect sizes and absolute risk reductions that are large enough to matter to patients

What gets desk-rejected in 2 days:

• Subspecialty research that only cardiologists, only oncologists, or only dermatologists would read. This is the #1 desk rejection reason. These papers belong in JAMA Network specialty journals, which are excellent journals, not consolation prizes

• Studies reporting p-values without clinically meaningful effect sizes. JAMA pioneered the move away from p-value fixation. A treatment that produces a 0.2% absolute risk reduction will not impress editors regardless of the p-value

• Manuscripts missing Key Points, structured abstract, or EQUATOR-compliant reporting. These are format requirements, but missing them signals the author hasn't read the instructions, and editors notice

For the standing journal profile, submission rules, and related JAMA cluster pages, see the JAMA journal overview.

If the paper is strong but you are unsure whether it belongs in flagship JAMA or a JAMA Network specialty journal, run a JAMA journal-fit check before submission. The useful question is not whether JAMA is prestigious; it is whether the Key Points, abstract, and first table make a cross-specialty physician decision obvious.

JAMA is unquestionably a good journal, but that does not make it the best route for every strong clinical manuscript. The better question is whether the paper needs the flagship general-medicine audience or whether a JAMA Network specialty journal would produce a cleaner readership, reviewer pool, and career signal.

A manuscript can be too narrow for JAMA and still be excellent. A cardiology, oncology, neurology, pediatrics, or psychiatry paper may look more credible in the matching JAMA Network title if the central reader is a specialist. Conversely, a health-services, public-health, clinical-practice, or policy paper may deserve flagship JAMA even if it is less technically novel than a subspecialty paper, because the consequence crosses specialty boundaries.

1. The editorial rewrite. JAMA edits accepted papers more aggressively than any other major journal. The version that publishes will be substantially shorter, cleaner, and more accessible than what you submitted. This isn't optional, it's part of JAMA's brand. Don't fight the editing process. The rewritten version will be more readable and more cited by guideline committees.

2. The statistical review team. Every paper that passes desk review gets an independent statistical evaluation. JAMA's statisticians examine sample size justification, analysis appropriateness, missing data handling, and whether conclusions match data. This is co-equal with the clinical review, statistical problems caught here are included in the decision letter.

3. The "Importance" line. JAMA's structured abstract opens with "Importance:", a 1-2 sentence statement of why this question matters. Editors read it before anything else. If this line is generic ("hypertension is a leading cause of cardiovascular disease"), the editor already knows the paper isn't framed for JAMA. If it identifies a specific evidence gap that matters to practicing physicians, the next 30 seconds of the editor's attention are earned.

The single most common reason strong papers get desk-rejected from JAMA: the paper is excellent specialty research submitted to a general medical journal. A beautifully designed cardiology trial that only cardiologists would read about gets rejected not because the science is weak, but because the audience is narrow.

Authors make this mistake because they see JAMA's citation strength and think "my paper is good enough." But JAMA doesn't ask "is this good enough?" It asks "do 300,000 physicians across all specialties need to know about this?" If the answer is "only cardiologists need to know," JAMA Cardiology is likely the better strategic target.

The test: read your abstract to a physician in a completely different specialty. If they care about the result without you explaining why it matters, the paper might be JAMA-ready. If you have to explain why it's important for medicine broadly, it's a specialty journal paper.

For promotion, tenure, residency, fellowship, and grant committees, JAMA is a very strong signal because it says the work cleared a flagship general-medicine desk, statistical review, and a broad physician-readership test. That signal is strongest when the paper's title and Key Points make the cross-specialty consequence obvious.

The risk is strategic overtargeting. A long JAMA desk cycle followed by a specialty-network transfer can still be rational, but only if the team has time. If a trainee, early-career investigator, or grant-funded group needs a predictable publication path, a better-fit JAMA Network specialty journal may carry a cleaner field signal than a flagship submission whose general-medicine fit is weak.

Across our JAMA pre-submission reviews, the strongest manuscripts rarely fail because the study is unserious. They fail because the paper asks the editor to infer the general-medicine consequence instead of making it visible in the title, Key Points, abstract, and main tables. In our review of JAMA-targeted manuscripts, we see the same specific failure pattern repeatedly: authors prove scientific quality but not cross-specialty consequence. That editorial triage pattern matters because JAMA editors explicitly screen the title, Key Points, abstract, and tables for a broad physician decision. JAMA's public metrics make the journal look like a prestige target; the submission package has to make it read like a broad physician decision.

JAMA breadth is asserted in the cover letter but absent from the Key Points. In our pre-submission review work, this is the most common strong-paper failure pattern for JAMA. The cover letter says the finding changes practice across medicine, but the Key Points only name the specialty result. A diabetes, oncology, cardiology, or health-services manuscript can be excellent and still too narrow if the "Meaning" line does not state what a non-specialist physician should do differently. Before submission, the Key Points should pass a blunt test: if a general internist reads only those three bullets, can they identify the patient group, the decision, and the practical consequence without specialist translation?

The clinical effect is statistically clean but not physician-actionable. JAMA papers need methods that survive statistical review, but a correct p-value is not the same as a useful clinical message. We often see manuscripts with a well-powered cohort, appropriate adjustment, and a significant primary endpoint, yet the absolute effect size, confidence interval, or number-needed-to-treat logic is missing from the abstract. For JAMA, the abstract should not force the editor to calculate whether the result matters. It should name the magnitude of effect, the population in which it applies, and the limitation that would change interpretation.

The first table proves quality but not generalizability. Many JAMA-targeted manuscripts use Table 1 to show standard baseline variables, while the real editorial concern is whether the finding travels beyond one institution, region, payer group, or subspecialty clinic. If the study is single-center or geographically narrow, the methods and limitations need to explain why the result still matters for JAMA's broad readership. If they cannot, the paper may be better positioned for a JAMA Network specialty journal where the exact reader needs the result.

The manuscript belongs in JAMA Network, but the authors frame that as a downgrade. That framing hurts the submission strategy. A focused specialty paper is not automatically a failed JAMA paper; it may be a stronger JAMA Cardiology, JAMA Oncology, JAMA Neurology, or JAMA Internal Medicine paper. The practical decision is not "flagship or nothing." It is whether the manuscript's audience is all physicians, health-system leaders, and public-health readers, or a concentrated specialty group that will evaluate the study with more precise expectations.